Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Rhea-AI Summary

Olema Pharmaceuticals announced that its CEO, Sean P. Bohen, will participate in a virtual fireside chat at the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 11:30 a.m. ET. The event will be accessible via a live webcast on Olema’s website and archived for 14 days. Olema is focused on targeted therapies for women’s cancers, with its lead candidate, OP-1250, currently in clinical trials for ER-positive breast cancer.

SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 14, 2022, at 11:30 a.m. ET (8:30 a.m. PT).

A live webcast of the presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days. 

About Olema Oncology 
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with recurrent, locally advanced, or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

FAQ

What is the date and time of Olema's virtual fireside chat?

Olema's virtual fireside chat is scheduled for April 14, 2022, at 11:30 a.m. ET.

Where can I watch the Olema Pharmaceuticals webcast?

The Olema Pharmaceuticals webcast can be accessed on their website under the Investors & Media section.

What is Olema's lead product candidate?

Olema's lead product candidate is OP-1250, which targets ER-positive breast cancer.

What type of company is Olema Pharmaceuticals?

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on therapies for women’s cancers.

Is OP-1250 currently in clinical trials?

Yes, OP-1250 is undergoing evaluation in a Phase 1/2 clinical trial.